[1]
|
International Agency for Research on Cancer (2020) Latest Global Cancer Data: Cancer Burden Rises to 19.3 Million New Cases and 10.0 Million Cancer Deaths in 2020.
https://www.iarc.fr/fr/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/
|
[2]
|
Milani, A., Montemurro, F., Gioeni, L., et al. (2010) Role of Trastuzumab in the Management of HER2-Positive Metastatic Breast Cancer. Breast Cancer, 2, 93-109. https://doi.org/10.2147/BCTT.S6070
|
[3]
|
Menna, P., Minotti, G. and Salvatorelli, E. (2019) Cardiotoxicity of Targeted Cancer Drugs: Concerns, “The Cart Before the Horse,” and Lessons from Trastuzumab. Current Cardiology Reports, 21, Article No. 33.
https://doi.org/10.1007/s11886-019-1121-0
|
[4]
|
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Rolski, J., et al. (2009) BCIRG 006: Phase III Trial Comparing AC-T with AC-TH and with TCH in the Adjuvant Treatment of HER2-Amplified Early Breast Cancer Patients: Third Planned Efficacy Analysis. Cancer Research, 69, 62. https://doi.org/10.1158/0008-5472.SABCS-09-62
|
[5]
|
Perez, E.A., Suman, V.J., Davidson, N.E., Sledge, G.W., Kaufman, P.A., Hudis, C.A., et al. (2008) Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with or without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. Journal of Clinical Oncology, 26, 1231-1238.
https://doi.org/10.1200/JCO.2007.13.5467
|
[6]
|
Rastogi, P., Jeong, J., Geyer, C.E., Costantino, J.P., Romond, E.H., Ewer, M.S., et al. (2007) Five Year Update of Cardiac Dysfunction on NSABPB-31, a Randomized Trial of Sequential Doxorubicin/Cyclophosphamide (AC)-Paclitaxel (T) vs.AC-T with Trastuzumab (H). Journal of Clinical Oncology, 25, LBA513.
https://doi.org/10.1200/jco.2007.25.18_suppl.lba513
|
[7]
|
Suter, T.M., Procter, M., van Veldhuisen, D.J., Muscholl, M., Bergh, J., Carlomagno, C., et al. (2007) Trastuzumab- Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial. Journal of Clinical Oncology, 25, 3859-3865.
https://doi.org/10.1200/JCO.2006.09.1611
|
[8]
|
Chen, T., Xu, T., Li, Y., Liang, C., Chen, J., Lu, Y., et al. (2011) Risk of Crdiac Dysfunction with Trastuzumab in Breast Cancer Patients: A Meta-Analysis. Cancer Treatment Reviews, 37, 312-320.
https://doi.org/10.1016/j.ctrv.2010.09.001
|
[9]
|
李佳, 王阿曼, 吕海辰, 刘莹, 崔晓楠, 夏云龙, 等. 抗人类表皮生长因子受体-2药物疗效与“心”安全并重[J]. 中国医学前沿杂志(电子版), 2020(3): 19-26.
|
[10]
|
Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001) Use of Chemotherapy Plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer that Overexpresses HER2. New England Journal of Medicine, 344, 783-792. https://doi.org/10.1056/NEJM200103153441101
|
[11]
|
Sawyer, D.B., Zuppinger, C., Miller, T.A., Eppenberger, H.M. and Suter, T.M. (2002) Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1beta and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity. Circulation, 105, 1551-1554.
https://doi.org/10.1161/01.CIR.0000013839.41224.1C
|
[12]
|
Crone, S.A., Zhao, Y.Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., et al. (2002) ErbB2 is Essential in the Prevention of Dilated Cardiomyopathy. Nature Medicine, 8, 459-465. https://doi.org/10.1038/nm0502-459
|
[13]
|
Sengupta, P.P., Northfelt, D.W., Gentile, F., Zamorano, J.L. and Khandheria, B.K. (2008) Trastuzumab Induced Cardio Toxicity: Heart Failure at the Cross Roads. Mayo Clinic Proceedings, 83, 197-203.
https://doi.org/10.1016/S0025-6196(11)60840-9
|
[14]
|
Lu, C.Y., Srasuebkul, P., Drew, A.K., Chen, K., Ward, R.L. and Pearson, S.-A. (2013) Trastuzumab Therapy in Australia: Which Patients with HER2 + Metastatic Breast Cancer Are Assessed for Cardiac Function? Breast, 22, 482-427.
https://doi.org/10.1016/j.breast.2013.04.011
|
[15]
|
Swain, S.M., Ewer, M.S., Cortés, J., Amadori, D., Miles, D., Knott, A., et al. (2013) Cardiac Tolerability of Pertu- Zumab Plus Trastuzumab Plus Docetaxel in Patients with HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. Oncologist, 18, 257-264.
https://doi.org/10.1634/theoncologist.2012-0448
|
[16]
|
Lipshultz, S.E., Rifai, N., Sallan, S.E., Lipsitz, S.R., Dalton, V., Sacks, D.B., et al. (1997) Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury. Circulation, 96, 2641-2648.
https://doi.org/10.1161/01.CIR.96.8.2641
|
[17]
|
周佳琳, 王照东方, 张静, 万冬桂. 李佩文教授辨治乳腺癌治疗相关心脏毒性经验[J]. 中国医药导报, 2020, 17(34): 146-149.
|
[18]
|
姚铁柱, 徐志宏, 马景涛, 张宁, 高威, 张守德, 等. 心脉隆注射液对曲妥珠单抗和蒽环类药物序贯化疗乳腺癌患者致心脏毒性气虚血瘀证的保护作用[J]. 中国实验方剂学杂志, 2016, 22(6): 154-158.
|
[19]
|
张洋, 刘晓菲, 朱晴, 王楠. 加味生脉饮对HER-2阳性乳腺癌赫赛汀所致心脏毒性防治作用研究[J]. 现代中西医结合杂志, 2020, 29(24): 2640-2643, 2683.
|
[20]
|
桑震池, 徐三彬, 钱俊峰, 许国军, 汪蔚青, 王大英, 等. 黄芪总皂苷对心力衰竭大鼠心功能及左室重构的影响[J]. 中西医结合心脑血管病杂志, 2017, 15(17): 2114-2116.
|
[21]
|
朱慧. 人参治疗慢性心力衰竭临床观察[J]. 光明中医, 2019, 34(8): 1208-1210.
|
[22]
|
乔翠霞, 张新峰, 程旭峰, 刘琦, 蔡小平. 生脉散加味与多西他赛联合曲妥珠单克隆抗体对有心脏高危因素的高龄胃癌患者的临床疗效[J]. 中国老年学杂志, 2019, 39(12): 2876-2878.
|